🦠
COVID-19
35 articles analyzed — Average score : 49/100
Grade distribution
Authors' conclusions
Articles
B
Mostly reliable (75/100)
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Negative
RECOVERY Collaborative Group & Landray MJ·The Lancet·May 2021
B
Mostly reliable (73/100)
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. Negative
Simonovich VA et al.·The New England journal of medicine·Nov 2020
B
Mostly reliable (73/100)
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. Negative
Horby P et al.·The New England journal of medicine·Oct 2020
B
Mostly reliable (71/100)
Remdesivir for the Treatment of Covid-19 - Final Report. Positive
Beigel JH et al.·The New England journal of medicine·Oct 2020
B
Mostly reliable (68/100)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. Positive
Kalil AC et al.·The New England journal of medicine·Mar 2021
B
Mostly reliable (67/100)
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. Positive
Sadoff J et al.·The New England Journal of Medicine·Jun 2021
B
Mostly reliable (67/100)
Dexamethasone in Hospitalized Patients with Covid-19. Mixed
RECOVERY Collaborative Group et al.·New England Journal of Medicine·Feb 2021
B
Mostly reliable (66/100)
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Positive
RECOVERY Collaborative Group & RECOVERY Collaborative Group·Lancet (London, England)·May 2021
B
Mostly reliable (66/100)
Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers : A Randomized Controlled Trial. Negative
Bundgaard H et al.·Annals of Internal Medicine·Nov 2020
B
Mostly reliable (64/100)
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. Negative
Rosas IO et al.·The New England journal of medicine·Feb 2021
B
Mostly reliable (64/100)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Positive
Polack FP et al.·New England Journal of Medicine·Dec 2020
B
Mostly reliable (62/100)
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. Negative
Cavalcanti AB et al.·The New England journal of medicine·Jul 2020
B
Mostly reliable (62/100)
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. Positive
Voysey M et al.·Lancet·Jan 2021
B
Mostly reliable (60/100)
Physical interventions to interrupt or reduce the spread of respiratory viruses. Negative
Jefferson T et al.·The Cochrane database of systematic reviews·Jan 2023
B
Mostly reliable (60/100)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. Negative
Cao B et al.·The New England journal of medicine·Mar 2020
B
Mostly reliable (56/100)
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. Positive
Jayk Bernal A et al.·New England Journal of Medicine·Mar 2022
C
Nuanced (55/100)
A new coronavirus associated with human respiratory disease in China. Inconclusive
Wu F et al.·Nature·Feb 2020
C
Nuanced (51/100)
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. Mixed
Levin EG et al.·The New England Journal of Medicine·Oct 2021
C
Nuanced (51/100)
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Positive
Logunov DY et al.·Lancet (London, England)·Feb 2021
C
Nuanced (50/100)
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. Mixed
Andrews N et al.·The New England journal of medicine·Apr 2022
C
Nuanced (49/100)
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. Positive
Mevorach Dror et al.·The New England Journal of Medicine·Oct 2021
C
Nuanced (48/100)
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Mixed
Lopez Bernal J et al.·The New England journal of medicine·Jul 2021
C
Nuanced (47/100)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Mixed
Huang C et al.·Lancet (London, England)·Jan 2020
C
Nuanced (46/100)
Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. Positive
Charmet T et al.·Lancet Regional Health – Europe·Jul 2021
D
Unreliable (44/100)
6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Positive
Taquet M et al.·The Lancet Psychiatry·May 2021
D
Unreliable (44/100)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Positive
Voysey M et al.·The Lancet·Jan 2021
D
Unreliable (39/100)
SARS-CoV-2 Vaccination and Protection Against Clinical Disease: A Retrospective Study, Bouches-du-Rhône District, Southern France, 2021. Positive
Fournier PE et al.·Frontiers in Microbiology·Jan 2022
D
Unreliable (34/100)
Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. Mixed
Spyropoulos AC et al.·Journal of thrombosis and haemostasis : JTH·May 2020
D
Unreliable (27/100)
Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers. Inconclusive
Azzolini E et al.·JAMA·Aug 2022
E
Not reliable (25/100)
Protection against Covid-19 by BNT162b2 Booster across Age Groups. Positive
Bar-On YM et al.·N Engl J Med·Jan 2021
E
Not reliable (25/100)
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Positive
Bryant A et al.·American Journal of Therapeutics·Jun 2021
E
Not reliable (24/100)
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Positive
Khoury DS et al.·Nature medicine·May 2021
X
Invalidated (0/100)
Retracted
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. Negative
Mehra MR et al.·The New England Journal of Medicine·May 2020
X
Invalidated (0/100)
Retracted
RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Positive
Mehra MR et al.·The Lancet·May 2020
X
Invalidated (0/100)
Retracted
RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Positive
Gautret P et al.·International Journal of Antimicrobial Agents·Mar 2020